Article
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2020
Zhou Yue, Wang Bo, Qu Jinghan, Yu Fan, Zhao Yang, Li Shuyan, Zeng Ya, Yang Xi, Chu Li, Chu Xiao, Li Yida, Zou Liqing, Guo Tiantian, Ye Luxi, Liang Fei, Wang Shengping, Liu Quan, Ni Jianjiao, Zhu Zhengfei
Abstract excerpt
OBJECTIVES: Central nervous system (CNS) metastases are common complications in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs). However, for patients without baseline CNS metastasis, data regarding the incidence of symptomatic CNS metastasis with EGFR-TKI treatment and its risk factors are still rare. MATERIALS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.